↓ Skip to main content

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre…

Overview of attention for article published in Lancet Oncology, August 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news
1 news outlet
twitter
72 X users
facebook
2 Facebook pages

Citations

dimensions_citation
77 Dimensions

Readers on

mendeley
216 Mendeley